Cervical cancer is caused by high risk subtypes of the human papillomavirus. Prophylactic vaccination is not the standard of care in many countries, and where approved, implementation is far from complete. Once infected, prophylactic vaccines no longer prevent the development of cervical cancer, which can only be treated with surgery, chemotherapy or radiotherapy. With an estimated impact of almost 500,000 new cases of cervical cancer and 274,000 deaths per year worldwide, the need for an effective therapy to treat recurrent/metastatic cervical cancer is extremely high. IMMUNISA facilitates a multidisciplinary collaboration between leading European clinical sites specialised in cervical cancer, a partner providing excellent regulatory service and a cutting-edge biotech enterprise to find an effective targeted immunotherapy approach to induce an immune response directed at the tumour.
IMMUNISA is funded by Horizon 2020: the European Union Framework Programme for Research and Innovation, Project N° 731623.